Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic basal cell carcinoma, however, has largely gone untested. Because PD-Ligand-1 (PD-L1) expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipson, Evan J., Lilo, Mohammed T., Ogurtsova, Aleksandra, Esandrio, Jessica, Xu, Haiying, Brothers, Patricia, Schollenberger, Megan, Sharfman, William H., Taube, Janis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360064/
https://www.ncbi.nlm.nih.gov/pubmed/28344809
http://dx.doi.org/10.1186/s40425-017-0228-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360064/
https://www.ncbi.nlm.nih.gov/pubmed/28344809
http://dx.doi.org/10.1186/s40425-017-0228-3

Ejemplares similares